Gates Foundation Strategic Investment Fund Logo

Vedanta Biosciences

Vedanta Biosciences is creating a new class of drugs to modulate the human microbiome. Vedanta is pioneering the rational design of drugs made of defined consortia of bacteria that are essential dwellers of the gut ecosystem that perform critical functions Read More

Butterfly Network

Butterfly has created the world’s first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation’s vision of an ecosystem where hardware, software, data and expertise come together Read More

Sera Prognostics

Sera Prognostics, based in Salt Lake City, UT, is developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications.

Kymab

Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.

Press Release: Kymab secures US $100 million Series C funding

Kymab November 24, 2016 Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announced today that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. Read More